Latest glioblastoma multiforme Stories
Company Reported Positive Preliminary Responses in Phase I/II Trial Patients; Feuerstein Falsely Claims There Is No Positive Trial Information BETHESDA, Md., May
BETHESDA, Md., May 27, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio) announced today that the Company will host a conference call and webcast with CEO Linda Powers today, May
Initial Responses Seen Before Patients Have Completed Treatments; BETHESDA, Md., May 27, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing
American Brain Tumor Association Conference to Be Held July 25 - 26 Chicago, IL (PRWEB) May 22, 2014 The American Brain Tumor Association will host its
In Addition, Toca 511 Clinical Data to be Presented at American Society of Clinical Oncology Annual Meeting SAN DIEGO, May 22, 2014 /PRNewswire/ --
VANCOUVER, British Columbia and MENLO PARK, Calif., May 20, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB:
A registry of 457 recurrent glioblastoma patients shows that patients treated commercially with NovoTTF Therapy in 2012 and 2013 achieved the longest median overall survival yet shown in non-experimental
Harvard Stem Cell Institute scientists at Massachusetts General Hospital have a potential solution for how to more effectively kill tumor cells using cancer-killing viruses.
Just because you can’t see something doesn’t mean it’s not there.
30mg/m2 dose cohort had been completed; enrollment of 40mg/m2 cohort has been initiated VANCOUVER, British Columbia and MENLO PARK, Calif., May 16, 2014 /PRNewswire/ --
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.